Page last updated: 2024-08-18

pyrazolanthrone and Hematologic Malignancies

pyrazolanthrone has been researched along with Hematologic Malignancies in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Colombo, M; Diaz, Z; Komarnitsky, PB; Kourelis, M; Mann, KK; Marcoux, S; Miller, WH	1

Other Studies

1 other study(ies) available for pyrazolanthrone and Hematologic Malignancies

Article	Year
A novel arsenical has antitumor activity toward As2O3-resistant and MRP1/ABCC1-overexpressing cell lines. Leukemia, 2008, Volume: 22, Issue:10 Topics: Animals; Anthracenes; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Drug Resistance, Neoplasm; Glutathione; Hematologic Neoplasms; Humans; JNK Mitogen-Activated Protein Kinases; MAP Kinase Kinase 4; Mice; Multidrug Resistance-Associated Proteins; Oncogene Proteins, Fusion; Oxidative Stress; Oxides	2008

Article

Year

A novel arsenical has antitumor activity toward As2O3-resistant and MRP1/ABCC1-overexpressing cell lines.

Leukemia, 2008, Volume: 22, Issue:10

Topics: Animals; Anthracenes; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Drug Resistance, Neoplasm; Glutathione; Hematologic Neoplasms; Humans; JNK Mitogen-Activated Protein Kinases; MAP Kinase Kinase 4; Mice; Multidrug Resistance-Associated Proteins; Oncogene Proteins, Fusion; Oxidative Stress; Oxides

2008